Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy

• Status: Unknown status
• Trial end date: 2019-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Examine the efficacy of brinzolamide for the treatment of central serous chorioretinopathy

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tel-Aviv Sourasky Medical Center
• Treatments: Brinzolamide

Criteria

Inclusion Criteria:

• Central serous chorioretinopathy (CSC) affecting the fovea, non-resolving after 4 months of follow-up

• Optical coherence tomography (OCT) shows foveal subretinal fluid

• Fluorescein angiography and indocyanine green confirm the diagnosis

Exclusion Criteria:

• Any other ophthalmic condition that may lead to subretinal fluid

• Choroidal neovascularization

• Myopia > -6D

• Previous treatment for CSC in the past 6 months

• Known allergy to fluorescein or indocyanin green

• Known allergy for brinzolamide

• Pregnancy, breast feeding